Dalman AQ

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dalman AQ

Quick Facts

Property Description
Active ingredient Fluticasone Propionate (INN)
Form Nasal Spray (Aqueous Suspension)
Pharmacological class Corticosteroid (Synthetic Glucocorticoid)
Common use Symptomatic management of seasonal and perennial rhinitis
Origin Synthetic (Fluorinated derivative)

What Type of Medicine Is Dalman AQ? (Definition & Classification)

Dalman AQ is the commercial name for a medication whose active ingredient is Fluticasone Propionate, a potent, synthetic compound. Pharmacologically, this medication belongs to the family of corticosteroids, specifically functioning as a glucocorticoid. Fluticasone Propionate is recognized globally as a mainstay in the treatment of nasal inflammation.

The drug is formulated as a metered-dose Nasal Spray containing an aqueous suspension for topical administration directly to the nasal mucosa. This precise delivery system is a key differentiating factor, as this form is characterized by high local activity and low systemic bioavailability. The localized effect minimizes the likelihood of widespread bodily effects.

Primary Purpose: Anti-Inflammatory Relief for Rhinitis (General Benefit)

The general purpose of Dalman AQ is to serve as a strong anti-inflammatory and anti-allergic agent to address the core symptoms of chronic nasal irritation and immune overreaction. Its primary utility is the management of discomfort associated with both seasonal allergic rhinitis, such as hay fever, and ongoing perennial rhinitis.

By acting as a synthetic glucocorticoid, the medication dampens the complex inflammatory cascade in the nasal passages, suppressing the release and action of multiple natural inflammatory mediators. Intranasal Fluticasone Propionate is used for the control of chronic nasal symptoms. This focused action helps to reduce tissue swelling and fluid production, relieving sneezing, itching, and congestion, thereby restoring comfortable nasal airflow.

Regulatory References

  1. Fluticasone Propionate Nasal Spray Label

What side effects are possible with Dalman AQ?

The safety profile of Dalman AQ is primarily characterized by localized effects due to its topical administration. Adverse reactions are classified by frequency as observed in regulatory documentation (e.g., FDA Prescribing Information and EMA SmPC).

Adverse Reaction Scope

Category Details (Derived from Official Regulatory Labels)
Frequency classification Very Common: Epistaxis (nosebleed). Common: Headache, nasal dryness, nasal irritation, throat irritation, unpleasant taste, unpleasant smell. Very Rare: Systemic hypersensitivity reactions, Glaucoma, raised intraocular pressure, cataracts, Nasal septal perforation. Not Known: Blurred vision, nasal ulceration.
System-organ classes involved Respiratory, Thoracic and Mediastinal Disorders; Nervous System Disorders; Immune System Disorders; Eye Disorders; Endocrine System Disorders.
Serious adverse reactions Severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm). Ocular effects like glaucoma and cataracts, particularly with prolonged use. Adrenal suppression and hypercorticism are documented systemic risks.

Safety Considerations

Population-specific safety considerations address the potential for growth rate reduction in pediatric patients, which requires monitoring. For patients with severe hepatic impairment, increased systemic exposure is anticipated, potentially raising the risk of systemic corticosteroid adverse effects. Ocular adverse reactions are specifically associated with long-term exposure.

Safety-related restrictions include avoiding use after recent nasal surgery, nasal trauma, or in the presence of unhealed nasal ulcers. Caution is also warranted in patients with local or systemic infections (e.g., ocular herpes simplex) due to the general immunosuppressive class effect of corticosteroids.

The official safety information structures the risk assessment by distinguishing common, non-serious local effects from rare, but clinically significant, systemic and ocular concerns.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Dalman AQ primarily by the risk of Chronic Systemic Exposure resulting from prolonged use at dosages higher than recommended. Overdose does not typically arise from a single, acute incident but from excessive duration or quantity. Documented overdose presentations are related to systemic corticosteroid effects, most notably Hypercorticism and the potential for Adrenal Suppression (suppression of the Hypothalamic-Pituitary-Adrenal or HPA axis).

When suspected overdose occurs, or if clinical signs of systemic effects appear, immediate action is required: individuals must seek immediate medical help or contact a Poison Control Center right away, as stated in official documents. Management is generally symptomatic and supportive. If HPA axis suppression is confirmed, the medication must be discontinued slowly, consistent with established procedures for systemic corticosteroid withdrawal.

Specific population notes exist in the prescribing information: Pediatric patients require monitoring of their growth rate due to the documented potential for systemic effects from higher than recommended dosages. Caution is also noted for patients with severe hepatic impairment as drug clearance may be slower.

Therapeutic Uses of Dalman AQ

Quick Facts

  • Relief of Nasal Symptoms: Used to help manage sneezing, itching, and nasal discharge.
  • Allergic Rhinitis: Indicated for both seasonal (e.g., hay fever) and year-round allergic rhinitis.
  • Non-Allergic Rhinitis: May be administered to help relieve symptoms not caused by allergies.

Dalman AQ is a therapeutic option intended to manage symptoms related to inflammation within the nasal lining. Its primary indication is the treatment and prophylaxis of allergic rhinitis, which includes both seasonal allergies (such as hay fever) and perennial (year-round) rhinitis. The medication is delivered locally to the nasal mucosa.

The therapeutic action of Dalman AQ helps to relieve common discomforts associated with these conditions. This may include helping to reduce sneezing, nasal itching, and excessive discharge. It is also used to help diminish nasal congestion, contributing to improved breathing and overall comfort for individuals with rhinitis. Consistent and regular administration is necessary for patients to experience the maximum therapeutic effect.

Regulatory References

  1. MedlinePlus drug information on Fluticasone Nasal Spray

Eligibility and Restrictions for Use

Who Can and Cannot Use Dalman AQ?

The population eligibility for Dalman AQ (Fluticasone Propionate Nasal Spray) is strictly defined by regulatory authorities, outlining both approved users and groups for whom the medicine is prohibited or requires caution.

Eligibility Scope

Classification Population Constraint
Contraindicated Patients with known Hypersensitivity to any ingredient. Absolute prohibition from use.
Allowed Adults and Adolescents (aged 12 years and older). Pediatric patients aged 4 years and older. Approved population for use.
Not Recommended Children younger than 4 years of age. Safety and efficacy have not been established.
Restricted Use Patients with recent nasal trauma, surgery, or ulcers. Avoid use until complete healing has occurred.

Condition-Based Eligibility Rules

Patients with certain co-existing conditions require caution, close monitoring, or specific considerations, as documented in official labeling:

  • Systemic Risk Factors: Use with caution in patients with active or quiescent tuberculous infections, or systemic fungal, bacterial, viral, or parasitic infections. Close monitoring is warranted for patients with a history of glaucoma or cataracts.
  • Organ Function: Caution is advised for patients with severe hepatic impairment due to the potential for increased systemic exposure. No specific dosage adjustment is required for renal impairment.
  • Pregnancy and Lactation: Use during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus due to insufficient data. Caution is advised during breastfeeding, as it is unknown if the drug is excreted into human milk.

What should I know about interactions with other medicines?

Dalman AQ (flurazepam) is a central nervous system (CNS) depressant, and its primary concern for interactions involves agents that also slow brain activity. Concomitant use with other CNS depressants can lead to additive effects, significantly increasing the risk of sedation, profound respiratory depression, coma, and even death.

Major Interactions (Increased CNS Depression)

  • Opioids (e.g., codeine, morphine, fentanyl): Co-administration is generally avoided due to the high risk of serious adverse outcomes. If necessary, dosages should be limited, and patients must be closely monitored.
  • Alcohol: Avoid consumption entirely, as it substantially increases sedation and impairment of judgment, thinking, and motor skills.
  • Other Sedative/Hypnotics (e.g., other benzodiazepines, zolpidem, eszopiclone)
  • Antipsychotics, Antidepressants, Antihistamines, and Muscle Relaxants

Metabolic Interactions

Flurazepam is metabolized in the liver. Drugs that inhibit certain liver enzymes (CYP450 3A4) can slow the breakdown of flurazepam, potentially increasing its concentration in the blood and enhancing its sedative effects. Examples of potent inhibitors include certain antifungal agents (e.g., ketoconazole) and some HIV protease inhibitors (e.g., atazanavir). Dose adjustments and close monitoring may be required.

Mechanism of Action

How Dalman AQ Works: The Mechanism of Action

Genomic Reprogramming of the Inflammatory Cascade

The core action involves Fluticasone Propionate binding as an agonist to the intracellular Glucocorticoid Receptor (GR). This complex translocates to the cell nucleus to modulate gene expression, a process involving transactivation and transrepression. This mechanism targets the genetic blueprint of the inflammatory process, reducing the cellular production of pro-inflammatory proteins (like cytokines) while simultaneously enhancing the synthesis of anti-inflammatory proteins (like Annexin A1).


Broad-Spectrum Mediator and Edema Control

The genetic modulation influences several parallel pathways. By inhibiting the enzyme Cytosolic Phospholipase A2 ( cPLA2), the drug’s action results in the reduced synthesis of mediators, including Prostaglandins and Leukotrienes. This comprehensive blockade, combined with reduced vascular permeability and local vasoconstriction, restricts fluid leakage into the nasal tissue, leading to a physiological decrease in tissue edema (swelling).


⏳ Constraint of Genomic Onset

The time course of the drug’s mechanistic effect is intrinsically linked to the time required for these molecular and cellular changes to occur. Because the mechanism relies on gene transcription and protein turnover, the mechanism is physiologically constrained from rapid anti-inflammatory action and requires consistent application to sustain high levels of newly synthesized anti-inflammatory proteins.

Dosage and Administration Information

Administration Guidelines for Dalman AQ

Dalman AQ (Fluticasone Propionate) is a nasal spray suspension for intranasal administration only. Full therapeutic benefit requires regular usage, as maximum relief may not be achieved until after 3 to 4 days of treatment, and full benefit may require continuation for several weeks.

Dosing Rules

Age Group Starting Dose Maximum Daily Dose
Adults and Children 12+ Two sprays in each nostril once daily Four sprays in each nostril
Children 4–11 Years One spray in each nostril once daily Two sprays in each nostril

*The starting dose is typically taken in the morning. An increased dose of up to twice daily (morning and evening) may be required in some cases.

Preparation and Administration Steps

  1. Preparation (Priming): Before the first use or if the device has not been used for a few days, the bottle must be primed by pumping the spray a few times until a fine mist appears.
  2. Procedure: Gently shake the bottle. After removing the dust cap, gently blow the nose to clear the nostrils. Close one nostril with a finger, insert the nozzle into the other nostril, and tilt the head slightly forward while keeping the bottle upright.
  3. Application: While breathing in slowly through the nose, press down firmly on the collar to release one spray. Breathe out through the mouth. Repeat for the same nostril if a second spray is required, then repeat the entire process for the other nostril.
  4. Cleaning: The nozzle must be wiped with a clean tissue and the dust cap replaced after use. Periodically, the nozzle should be removed, cleaned, and dried, requiring the spray to be re-primed afterward.

Missed Dose

If a dose is missed, it should be used as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. Do not use a double dose to compensate for the missed one.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Drug X

Research examined the frequency of severe migraines in patient populations. A large-scale Phase III Randomized Controlled Trial (RCT) evaluated monthly migraine days as a primary endpoint in study participants. Some studies included control groups receiving existing preventive compounds, allowing for a comparison of clinical profiles.


Combination Therapy

Research investigated the clinical profile of Drug X when co-administered with a common acute treatment. One study evaluated the protocol of using the combination during the prodromal phase (the earliest warning signs of a migraine attack) to assess its potential effect on the subsequent headache.


Ongoing Research

Current research is exploring new applications for the compound. Some exploratory studies suggest Drug X is being investigated for use in other severe headache disorders, such as cluster headaches. While the evidence in these secondary indications remains limited, this indicates the scope of current research on the compound and its potential clinical application beyond its primary use.

Key Studies & References

  1. NICE Guideline NG198: Migraine: Diagnosis and management (Relevant Sections on CGRP Antagonists)

Frequently Asked Questions (FAQ)

Common questions about Dalman AQ (FAQ)

Q: Is Dalman AQ a controlled substance or scheduled drug?

The active ingredient in Dalman AQ, Fluticasone Propionate, is a corticosteroid.

Official regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), do not classify this compound as a controlled or scheduled substance.

Q: How long does Dalman AQ stay in the body after the last dose?

Pharmacokinetics data indicates that the compound has an elimination half-life of approximately 7.8 hours following intravenous administration.

However, Dalman AQ is administered nasally, and its systemic absorption into the rest of the body is extremely low, reflecting its very low systemic absorption when administered nasally.

Q: Can taking Dalman AQ affect the effectiveness of hormonal birth control?

Official information does not indicate any known or clinically significant drug-drug interactions between Dalman AQ nasal spray and commonly used hormonal contraceptives.

Q: Does Dalman AQ interact negatively with herbal supplements like St. John’s Wort or CBD?

Dalman AQ is metabolized by an enzyme in the liver called CYP3A4. Regulatory documents note that certain strong herbal enzyme inhibitors, such as St. John’s Wort, could potentially slow the breakdown of the drug.

The official product information contains warnings regarding potential interactions with CYP3A4 inhibitors.

Q: Can Dalman AQ be safely used by older adults (e.g., people over 65)?

Official studies have not identified geriatric-specific problems that would prevent the use of Dalman AQ in older adults.

Official documentation advises that caution may be required, particularly in older patients due to a higher likelihood of age-related issues with liver, kidney, or heart function.

Q: Is Dalman AQ known to cause withdrawal symptoms when stopped?

Withdrawal symptoms are generally considered unlikely when Dalman AQ is used appropriately and as directed.

However, prolonged use at very high dosages may rarely lead to systemic issues like adrenal suppression, in which case discontinuation may need to be managed gradually, as described in official labeling.

Q: Are there any lifestyle activities, like driving, that are restricted while using Dalman AQ?

Official product information does not impose general restrictions on driving or operating machinery for Dalman AQ alone.

Caution is only typically advised when taking Dalman AQ in combination with other medicines that may cause somnolence (drowsiness).

Q: Can Dalman AQ affect my ability to operate machinery or focus on tasks?

Dalman AQ (Fluticasone Propionate) is not commonly associated with effects that reduce mental alertness or focus.

If using a combination product that includes an antihistamine, however, the risk of somnolence (drowsiness) may be present, which could impair focus and motor coordination.

Q: Why do some people report feeling unusually tired when taking Dalman AQ?

Adverse event reports for fluticasone preparations include 'unusual tiredness or weakness' and 'malaise/fatigue.'

This is considered uncommon for the nasal spray alone but is sometimes associated with systemic corticosteroid effects like adrenal suppression.

Q: Is it normal to experience a change in appetite after starting Dalman AQ?

Official documents list changes in appetite and weight gain as rare side effects associated with systemic corticosteroid effects, such as hypercorticism.

Conversely, a loss of appetite may also be a rare sign of adrenal suppression, as noted in regulatory warnings.

Q: Can Dalman AQ cause changes in mood or behavior?

Official adverse event reports indicate that changes in mood or behavior, including aggression, agitation, depression, and restlessness, have been rarely reported during fluticasone use.

Q: Are there any known issues with Dalman AQ for people with diabetes or high blood pressure?

Regulatory labels note that corticosteroids can very rarely be associated with metabolic effects like hyperglycemia (high blood sugar).

Official documentation notes that monitoring may be required for patients with these conditions.

Q: What should I know about taking Dalman AQ if I have a history of a heart condition?

Rare cardiovascular effects, such as palpitations (a noticeable rapid or irregular heartbeat) and tachycardia (fast heartbeat), have been reported in official documents.

Official product information indicates that monitoring may be required for patients with a history of heart conditions.

Q: Are there any official guidance or data about Dalman AQ and weight change?

Weight gain is listed in official documents as a rare side effect, generally associated with systemic corticosteroid effects.

Conversely, a loss of weight or appetite may be a rare sign of adrenal suppression.

Q: What information is available about Dalman AQ's effect on sleep patterns?

The active ingredient fluticasone propionate is not commonly known to cause sleep disturbances.

However, rare side effects such as fatigue, malaise, and restlessness are reported in official documents, which could potentially affect sleep quality.

Q: Is it normal to have mild stomach upset when first starting Dalman AQ?

According to official regulatory safety data, gastrointestinal effects such as nausea, vomiting, and abdominal discomfort have been reported as rare or less common side effects associated with fluticasone preparations.

Q: Can I take Dalman AQ if I have certain psychiatric conditions?

Rare psychiatric side effects, including agitation, aggression, depression, and restlessness, have been reported in association with fluticasone use.

Official product information advises caution for patients with certain pre-existing psychiatric conditions.

Q: Are there any known interactions between Dalman AQ and vaccines?

Official documents do not list specific known interactions with routine vaccines.

However, regulatory warnings note that corticosteroids may be generally immunosuppressive, potentially affecting the body’s expected antibody response to vaccines, particularly if the drug is used at higher doses.

How should Dalman AQ be stored and disposed of?

How to Store and Dispose of Dalman AQ?

The storage and handling of Dalman AQ Nasal Spray are governed by regulatory requirements to maintain product stability and ensure safety.

Official Storage Conditions

Requirement Description
Temperature Limit Store below 25^circC (77°F).
Environmental Protection Must be protected from frost (do not freeze) and protected from light.
Child Safety Keep out of the sight and reach of children.

The medication must not be used after the expiry date printed on the label and carton.

Disposal Instructions

Unused or expired Dalman AQ must not be disposed of via household waste or wastewater. Individuals are advised to consult a pharmacist regarding the proper procedure for safely discarding any medicine that is no longer required, a measure designed to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dalman AQ found in:

A-Z Index: